创伤性脑损伤患者呼吸机相关性肺炎的发生率、危险因素及对结局的影响:一项大型多中心前瞻性观察纵向研究分析
本研究基于CENTER-TBI数据集,纳入962例接受机械通气≥48小时且ICU停留≥72小时的创伤性脑损伤患者,分析呼吸机相关性肺炎(VAP)的发生率、时机、危险因素及对6个月结局的影响。结果显示20.4%发生VAP,中位5天,VAP延长机械通气和ICU停留时间,但不增加死亡率或恶化神经结局。
要点
- 创伤性脑损伤患者VAP发生率为20.4%,中位发生时间5天。
- VAP延长机械通气时间和ICU停留时间,但不增加6个月死亡率或不良神经结局。
- 年龄、胸部创伤、组胺受体拮抗剂使用和抗生素预防与VAP风险相关。
核心结论
- 创伤性脑损伤后VAP发生率低于既往描述,对ICU停留时间有不利影响,但不影响死亡率和神经结局。
研究设计与样本
- 基于CENTER-TBI大型多中心前瞻性观察纵向研究数据集,纳入962例创伤性脑损伤患者,比较VAP与非VAP患者特征,并用Glasgow结局扩展量表评估6个月结局。
主要发现
- 196例(20.4%)发生VAP,中位插管后5天(IQR 3-7天)。
- VAP患者更年轻(中位39.5岁 vs 51岁,P<.001),酒精滥用(36.6% vs 27.6%,P=.026)、药物滥用(10.1% vs 4.2%,P=.009)、胸部创伤(53% vs 43%,P=.014)及ICU期间呼吸衰竭(69.9% vs 28.1%,P<.001)比例更高。
- VAP患者机械通气时间更长(中位15天 vs 8天,P<.001),ICU停留时间更长(中位20天 vs 13天,P<.001)。
- 6个月总死亡率为22%,VAP与死亡率或神经结局恶化无关。
关键数值与推荐
- 年龄(HR 0.99;95%CI 0.98-0.99;P=.001)、胸部创伤(HR 1.4;95%CI 1.03-1.90;P=.033)、组胺受体拮抗剂摄入(HR 2.16;95%CI 1.37-3.39;P=.001)和抗生素预防(HR 0.69;95%CI 0.50-0.96;P=.026)与VAP风险相关。
临床怎么用
- 对创伤性脑损伤机械通气患者应关注VAP预防,尤其年轻、胸部创伤、使用组胺受体拮抗剂者,抗生素预防可能与较低VAP风险相关,但需权衡利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No large prospective data, to our knowledge, are available on ventilator-associated pneumonia (VAP) in patients with traumatic brain injury (TBI). RESEARCH QUESTION: To evaluate the incidence, timing, and risk factors of VAP after TBI and its effect on patient outcome. STUDY DESIGN AND METHODS: This analysis is of the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury data set, from a large, multicenter, prospective, observational study including patients with TBI admitted to European ICUs, receiving mechanical ventilation for ≥ 48 hours and with an ICU length of stay (LOS) ≥ 72 hours. Characteristics of patients with VAP vs characteristics of patients without VAP were compared, and outcome was assessed at 6 months after injury by using the Glasgow Outcome Scale Extended. RESULTS: The study included 962 patients: 196 (20.4%) developed a VAP at a median interval of 5 days (interquartile range [IQR], 3-7 days) after intubation. Patients who developed VAP were younger (median age, 39.5 [IQR, 25-55] years vs 51 [IQR, 30-66] years; P < .001), with a higher incidence of alcohol abuse (36.6% vs 27.6%; P = .026) and drug abuse (10.1% vs 4.2%; P = .009), more frequent thoracic trauma (53% vs 43%; P = .014), and more episodes of respiratory failure during ICU stay (69.9% vs 28.1%; P < .001). Age (hazard ratio [HR], 0.99; 95% CI, 0.98-0.99; P = .001), chest trauma (HR, 1.4; 95% CI, 1.03-1.90; P = .033), histamine-receptor antagonist intake (HR, 2.16; 95% CI, 1.37-3.39; P = .001), and antibiotic prophylaxis (HR, 0.69; 95% CI, 0.50-0.96; P = .026) were associated with the risk of VAP. Patients with VAP had a longer duration of mechanical ventilation (median, 15 [IQR, 10-22] days vs 8 [IQR, 5-14] days; P < .001) and ICU LOS (median, 20 [IQR, 14-29] days vs 13 [IQR, 8-21] days; P < .001). However, VAP was not associated with increased mortality or worse neurological outcome. Overall mortality at 6 months was 22%. INTERPRETATION: VAP occurs less often than previously described in patients after TBI and has a detrimental effect on ICU LOS but not on mortality and neurological outcome. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT02210221; URL: www.clinicaltrials.gov.
引用
- Robba C, Rebora P, Banzato E, et al. Incidence, Risk Factors, and Effects on Outcome of Ventilator-Associated Pneumonia in Patients With Traumatic Brain Injury: Analysis of a Large, Multicenter, Prospective, Observational Longitudinal Study. Chest. 2020. PMID: 32634435. doi:10.1016/j.chest.2020.06.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。